Linda Al-Hassany

Linda Al-Hassany

Auto-generated profile, based on publicly available information

Linda Al-Hassany

Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, Rotterdam, 3015 GD, the Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2019 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
E(European Headache Federation School of Advanced Studies (EHF-SAS)
European Headache Federation School of Advanced Studies (EHF-SAS)
VFValentina Favoni
Valentina Favoni
LGLuca Giani
Luca Giani
LALinda Al-Hassany
Linda Al-Hassany
GAGian Maria Asioli
Gian Maria Asioli
SSSimona Sacco
Simona Sacco
Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the pathophysiology of migraine. Blockade of CGRP is a new therapeutic target for patients with migraine. CGRP and its receptors are distributed not only in the central and peripheral nervous system but also in the cardiovascular system, both in blood vessels and in the heart. We reviewed the current evidence on the role of CGRP in the cardiovascular system in order to understand the possible short- and long-term effect of CGRP blockade with monoclonal antibodies in migraineurs. In physiological conditions, CGRP has important vasodilating effects and is thought to protect organs from ischemia. Despite the aforementioned cardiovascular implication, preventive treatment with CGRP antibodies has shown no relevant cardiovascular side effects. Results from long-term trials and from real life are now needed.

1 July 2019 in Patient Preference and Adherence
Verified
Journal Article
Open access
LALinda Al-Hassany
Linda Al-Hassany
SKSanne M Kloosterboer
Sanne M Kloosterboer
BDBram Dierckx
Bram Dierckx
BKBirgit C P Koch
Birgit C P Koch
Nonadherence in children who use long-term medication is a serious problem and assessing adherence is an important step to provide solutions to this problem. Medication adherence can be measured by several methods, including (a) self-report questionnaires or structured interviews, (b) therapeutic drug monitoring (TDM), (c) electronic devices, and (d) pick-up/refill rates. The objective of this narrative review is to provide an overview of the literature about methods for the measurement of medication adherence in chronically ill children and adolescents. Therefore, we conducted a literature search by using multiple databases. Four methods of monitoring medication adherence are presented for the most described chronic diseases: asthma, HIV/AIDS, epilepsy, diabetes mellitus and ADHD. First, 10 commonly used self-report questionnaires and structured interviews are described, including the main characteristics, (dis)advantages and their validation studies. Second, the use of TDM in pediatric trials for medication adherence measurement is discussed. New sampling methods (e.g. dried blood spot) and sampling matrices (e.g. hair, saliva and urine) have shown their benefits for TDM in children. Third, electronic devices to measure medication adherence in children are presented, being developed for several drug administration routes. Fourth, the analyses, advantages and disadvantages of pharmacy data are discussed. The usage of this data requires specific calculations and interpretations to assess adherence. As presented in this review, every adherence method has specific (dis)advantages. When deciding which adherence method is applicable, validity and generalizability should be taken into account. Combining multiple methods seems to offer the best solution in the daily clinical practice.

16 February 2023 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
LALinda Al-Hassany
Linda Al-Hassany
HLHannah S. Lyons
Hannah S. Lyons
DBDeirdre M. Boucherie
Deirdre M. Boucherie
FFFatemeh Farham
Fatemeh Farham
KLKristin S. Lange
Kristin S. Lange
O(on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)
on behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)
Introduction: Migraine prophylactic therapy has changed over recent years with the development and approval of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. As new therapies emerged, leading headache societies have been providing guidelines on the initiation and escalation of such therapies. However, there is a lack of robust evidence looking at the duration of successful prophylaxis and the effects of therapy discontinuation. In this narrative review we explore both the biological and clinical rationale for prophylactic therapy discontinuation to provide a basis for clinical decision-making.Methods: Three different literature search strategies were conducted for this narrative review. These include i) stopping rules in comorbidities of migraine in which overlapping preventives are prescribed, notably depression and epilepsy; ii) stopping rules of oral treatment and botox; iii) stopping rules of antibodies targeting the CGRP (receptor). Keywords were utilized in the following databases: Embase, Medline ALL, Web of Science Core collection, Cochran Central Register of Controlled Trials, and Google Scholar.Discussion: Reasons to guide decision-making in stopping prophylactic migraine therapies include adverse events, efficacy failure, drug holiday following long-term administration, and patient-specific reasons. Certain guidelines contain both positive and negative stopping rules. Following withdrawal of migraine prophylaxis, migraine burden may return to pre-treatment level, remain unchanged, or lie somewhere in-between. The current suggestion to discontinue CGRP(-receptor) targeted mAbs after 6 to 12 months is based on expert opinion, as opposed to robust scientific evidence. Current guidelines advise the clinician to assess the success of CGRP(-receptor) targeted mAbs after three months. Based on excellent tolerability data and the absence of scientific data, we propose if no other reasons apply, to stop the use of mAbs when the number of migraine days decreases to four or fewer migraine days per month.There is a higher likelihood of developing side effects with oral migraine preventatives, and so we suggest stopping these drugs according to the national guidelines if they are well tolerated.Conclusion: Translational and basic studies are warranted to investigate the long-term effects of a preventive drug after its discontinuation, starting from what is known about the biology of migraine. In addition, observational studies and, eventually, clinical trials focusing on the effect of discontinuation of migraine prophylactic therapies, are essential to substantiate evidence-based recommendations on stopping rules for both oral preventives and CGRP(-receptor) targeted therapies in migraine.Graphical

25 December 2023 in Expert Review of Neurotherapeutics
Verified
Journal Article
Open access
RLRomy van Lohuizen
Romy van Lohuizen
JPJakob Paungarttner
Jakob Paungarttner
CLChristian Lampl
Christian Lampl
AMAntoinette MaassenVanDenBrink
Antoinette MaassenVanDenBrink
LALinda Al-Hassany
Linda Al-Hassany
Migraine, a neurovascular headache disorder, is a leading cause of disability worldwide. Within the multifaceted pathophysiology of migraine, hormonal fluctuations play an evident triggering and exacerbating role, pointing toward the need for identification and proper usage of both existing and new hormonal targets in migraine treatment. With a threefold higher incidence of migraine in women than in men, the authors delve into sex hormone-related events in migraine patients. A comprehensive overview is given of existing hormonal therapies, including oral contraceptives, intrauterine devices, transdermal and subcutaneous estradiol patches, gnRH-agonists, oral testosterone, and 5α reductase inhibitors. The authors discuss their effectiveness and risks, noting their suitability for different patient profiles. Next, novel evolving hormonal treatments, such as oxytocin and prolactin, are explored. Lastly, the authors cover hormonal conditions associated with migraine, such as polycystic ovary syndrome, endometriosis, and transgender persons receiving gender affirming hormone therapy, aiming to provide more personalized and effective solutions for migraine management. Rigorous research into both existing and new hormonal targets, as well as the underlying pathophysiology, is needed to support a tailored approach in migraine treatment, in an ongoing effort to alleviate the impact of migraine on individuals and society.

27 August 2024 in Neurology
Verified
Journal Article
Open access
LALinda Al-Hassany
Linda Al-Hassany
CACevdet Acarsoy
Cevdet Acarsoy
MIM. Kamran Ikram
M. Kamran Ikram
DBDaniel Bos
Daniel Bos
AMAntoinette MaassenVanDenBrink
Antoinette MaassenVanDenBrink
Although several lines of evidence suggest a link between migraine and cardiovascular events, less is known about the association between cardiovascular risk factors (CVRFs) and migraine. This knowledge is clinically important to provide directions on mitigating the cardiovascular risk in patients with migraine. We hypothesized that CVRFs are associated with a higher migraine prevalence. Therefore, our primary objective was to investigate sex-specific associations between CVRFs and lifetime prevalence of migraine. We performed cross-sectional analyses within an ongoing population-based cohort study (Rotterdam Study), including middle-aged and elderly individuals. By means of (structured) interviews, physical examinations, and blood sampling, we obtained information on the lifetime prevalence of migraine and the following traditional CVRFs: current smoking, obesity, hypercholesterolemia, hypertension, and diabetes mellitus. Similarly, we obtained information on quantitative component data on these CVRFs, including pack-years of smoking, lipid levels, systolic and diastolic blood pressure (BP), body mass index, and fasting glucose levels. Patients with migraine were age-matched to individuals without migraine, and we performed conditional logistic regression analyses to investigate the sex-stratified association of CVRFs with migraine. In total, 7,266 community-dwelling middle-aged and elderly persons were included (median age 66.6 [IQR 56.4-74.8] years, 57.5% females). The lifetime prevalence of migraine was 14.9%. In females, current smoking (odds ratio (OR) 0.72, 95% CI 0.58-0.90), more pack-years (OR per SD increase 0.91, 95% CI 0.84-1.00), diabetes mellitus (OR 0.74, 95% CI 0.56-0.98), and higher fasting glucose levels (OR per SD increase in glucose 0.90, 95% CI 0.82 - 0.98) were all related to a lower migraine prevalence while a higher diastolic BP related to a higher migraine prevalence (OR per SD increase 1.16, 95% CI 1.04-1.29). In males, no significant associations between CVRFs and migraine were observed. Traditional CVRFs were either unrelated or inversely related to migraine in middle-aged and elderly individuals, but only in females. In males, we did not find any association between CVRFs and migraine. Because only an increased diastolic BP was related to a higher migraine prevalence in females, our study contributes to the hypothesis that migraine is not directly associated with traditional CVRFs. Future studies are warranted to extrapolate these findings to younger populations.

25 February 2025 in Neurology
Verified
Journal Article
Closed access
CIChisato Ito
Chisato Ito
LALinda Al-Hassany
Linda Al-Hassany
TKTobias Kurth
Tobias Kurth
TGToivo Glatz
Toivo Glatz
This primer introduces the domains into which the aims of quantitative health research generally fall and provides tools to improve the methodological quality of observational clinical and population-based research articles-with a special focus on the field of neurology. Generally, research questions can be categorized into one of the following 3 data science domains: description, prediction, and causal inference. A descriptive question aims to quantify and describe the frequency and distribution of a given health condition in a certain population at or during a specific time. A predictive question aims to estimate either the probability of the presence of a given disease or health condition in an individual (diagnostic prediction) or the probability of an individual developing a disease of interest over a specified period (prognostic prediction). A causal question aims to estimate the causal effect of interest (estimand) of an exposure or intervention on an outcome in a given population. Depending on the research question, estimands could be the total causal effect, a mediated indirect effect, or effect (measure) modification by third variables, among others. Each of these domains comes with its own set of research methods, study designs, reporting guidelines, scientific language, strengths, and limitations, whereby the correct attribution of a research domain will have an impact in 3 ways: i) help authors to formulate appropriate research questions and choose and implement suitable study designs and methods; ii) allow reviewers and editors to assess studies with an increased focus on their clinical relevance, methodological advances, and novelty and quality of clinical evidence; and iii) facilitate clear communication of findings and clinical implications to the broader research community in neurology and related fields.